These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8742622)

  • 1. Portal hemodynamics and humoral factors involved in a portal hypertensive rabbit model.
    Lin PW; Shan YS
    Proc Natl Sci Counc Repub China B; 1995 Oct; 19(4):240-5. PubMed ID: 8742622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostacyclin production in acute, chronic, and long-term experimental portal hypertension.
    Sitzmann JV; Campbell K; Wu Y; St Clair C
    Surgery; 1994 Mar; 115(3):290-4. PubMed ID: 8128353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for role of prostacyclin as a systemic hormone in portal hypertension.
    Sitzmann JV; Li SS; Adkinson NF
    Surgery; 1991 Feb; 109(2):149-53. PubMed ID: 1992548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes of hemodynamics and concentrations of nitric oxide, endothelin, prostacyclin, and thromboxane A2 during portal cavity clamping and opening in portal hypertensive canines].
    Chi XJ; Wei JQ; Hei ZQ; Ge M; Liu DZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jul; 29(7):1337-40. PubMed ID: 19620047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of nitric oxide and cyclooxygenase inhibition on splanchnic hemodynamics in portal hypertension.
    Wu Y; Burns RC; Sitzmann JV
    Hepatology; 1993 Dec; 18(6):1416-21. PubMed ID: 8244267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic changes after ligation of a major branch of the portal vein in rats: comparison with rats with portal vein constriction.
    Um SH; Nishida O; Tokubayashi M; Kimura F; Takimoto Y; Yoshioka H; Inque R; Kita T
    Hepatology; 1994 Jan; 19(1):202-9. PubMed ID: 8276356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension.
    Vorobioff J; Bredfeldt JE; Groszmann RJ
    Am J Physiol; 1983 Jan; 244(1):G52-7. PubMed ID: 6849394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats.
    Fernandez M; Mejias M; Angermayr B; Garcia-Pagan JC; Rodés J; Bosch J
    J Hepatol; 2005 Jul; 43(1):98-103. PubMed ID: 15893841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of the development of portosystemic shunts in the maintenance of portal hypertension in rats].
    Braillon A; Koshy A; Lee SS; Girod C; Lebrec D
    Gastroenterol Clin Biol; 1988; 12(8-9):641-5. PubMed ID: 3215429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension.
    Oberti F; Sogni P; Cailmail S; Moreau R; Pipy B; Lebrec D
    Hepatology; 1993 Sep; 18(3):621-7. PubMed ID: 8359803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model.
    Sikuler E; Kravetz D; Groszmann RJ
    Am J Physiol; 1985 Jun; 248(6 Pt 1):G618-25. PubMed ID: 4003545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of partial portal decompression on portal blood flow and effective hepatic blood flow in man: a prospective study.
    Rosemurgy AS; McAllister EW; Godellas CV; Goode SE; Albrink MH; Fabri PJ
    J Surg Res; 1995 Dec; 59(6):627-30. PubMed ID: 8538157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension.
    Sitzmann JV; Bulkley GB; Mitchell MC; Campbell K
    Ann Surg; 1989 Mar; 209(3):322-7. PubMed ID: 2493776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology of portal hypertension.
    Bosch J; Pizcueta P; Feu F; Fernández M; García-Pagán JC
    Gastroenterol Clin North Am; 1992 Mar; 21(1):1-14. PubMed ID: 1568769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation.
    Hou MC; Cahill PA; Zhang S; Wang YN; Hendrickson RJ; Redmond EM; Sitzmann JV
    Hepatology; 1998 Jan; 27(1):20-7. PubMed ID: 9425912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyperdynamic status in a partial portal vein ligated (PVL) rat's portal hypertension model].
    Wang CT; Kuang YL; Chen ZP
    Zhonghua Wai Ke Za Zhi; 1994 Sep; 32(9):573-5. PubMed ID: 7720436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats.
    Muñoz J; Albillos A; Pérez-Páramo M; Rossi I; Alvarez-Mon M
    Am J Physiol; 1999 Mar; 276(3):G687-93. PubMed ID: 10070045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of flow and resistance in maintenance of portal hypertension in a rat model.
    Sikuler E; Groszmann RJ
    Am J Physiol; 1986 Feb; 250(2 Pt 1):G205-12. PubMed ID: 3953799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
    Fernandez M; Mejias M; Garcia-Pras E; Mendez R; Garcia-Pagan JC; Bosch J
    Hepatology; 2007 Oct; 46(4):1208-17. PubMed ID: 17654489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation.
    Pizcueta MP; García-Pagán JC; Fernández M; Casamitjana R; Bosch J; Rodés J
    Gastroenterology; 1991 Dec; 101(6):1710-5. PubMed ID: 1683327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.